Antibody drug conjugates (ADCs) are an emerging therapeutic modality for targeted cancer
treatment. They represent the unique amalgamation of chemotherapy and immunotherapy …

Abstract Currently, although> 10 antibody− drug conjugates (ADCs) are available in the
market, most of them (10 ADCs) have broad drug distribution, thereby potentially limiting …

Amanita poisoning has a high mortality rate. The α-amanitin toxin in Amanita is the main
lethal toxin. There is no specific detoxification drug for α-amanitin, and the clinical treatment …

Cathepsin B is a lysosomal cysteine protease, contributing to vital cellular homeostatic
processes including protein turnover, macroautophagy of damaged organelles, antigen …

Antibody-drug conjugates (ADCs) are a recent, revolutionary approach for malignancies
treatment, designed to provide superior efficacy and specific targeting of tumor cells …

The antibody-drug conjugates (ADCs) are one the fastest growing biotherapeutics in
oncology and are still in their infancy in gastrointestinal (GI) cancer for clinical applications to …

Nanocarriers are nanostructured vehicles employed to deliver anticancer drugs to the
targeted tumor sites in the body. Nanocarriers have been successfully employed to …

Cancer stem cells (CSCs), a subpopulation of cancer cells endowed with self-renewal,
tumorigenicity, pluripotency, chemoresistance, differentiation, invasive ability, and plasticity …

In antibody–drug conjugates (ADCs), monoclonal antibodies (mAbs) act as carriers for a
cytotoxic payload providing the therapy with targeted action against cells expressing a target …

Objective Antibody-drugs conjugates (ADCs) are novel drugs with highly targeted and tumor-
killing abilities and developing rapidly. This study aimed to evaluate drug discovery and …